GSE178309
Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support
Bone marrow mesenchymal stromal cells (MSCs) constitute one of the important components of the hematopoietic microenvironmental niche. There is in vitro evidence that marrow MSCs are able to support leukemia progenitor cell proliferation and survival and provide resistance to cytotoxic therapies.  How MSCs from leukemia marrow differ from normal counterparts and how they are influenced by the presence of leukemia stem, and progenitor cells are still incompletely understood.  In this work, we compared normal donor (ND) and acute myelogenous leukemia (AML) derived MSCs and found that AML-MSCs had increased adipogenic potential with improved ability to support survival of leukemia progenitor cells. To identify underlying changes, RNA-Seq analysis was performed.  Gene ontology and pathway analysis revealed adipogenesis to be among the set of altered biological pathways dysregulated in AML-MSCs as compared to ND-MSCs.  Expression of both SOX9 and EGR2 was decreased in AML-MSCs as compared to ND-MSCs.  Increasing expression of SOX9 decreased adipogenic potential of AML-MSCs and decreased their ability to support AML progenitor cells.  These findings suggest that AML-MSCs possess adipogenic potential which may enhance support of leukemia progenitor cells. Overall design: Three bone marrow derived MSC samples isolated from three different AML patients and three bone marrow derived MSC isolated from three different ND control donors resulted in reduction of hematopoietic stem cell content.